GO:2000158 positive regulation of ubiquitin-specific protease activity: Deubiquitination Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000158 describes any process that activates or increases the frequency, rate or extent of ubiquitin-specific protease (deubiquitinase) activity.
• Positive regulation of deubiquitinase activity is essential for stabilizing key oncoproteins and signaling effectors, including Snail1, Gasdermin E, KRAS, PPARγ, phospho-TBK1, and MAST1.
• Dysregulation of this process contributes to cancer metastasis, pyroptosis resistance, non-small cell lung cancer, hepatocellular carcinoma, and pathological cardiac remodeling.
• CRISPR/Cas9 genome-wide screening has identified deubiquitinase subfamily members such as USP1 that regulate cisplatin resistance, demonstrating the power of functional genomics in this field.
• USP7 targeting modulates anti-tumor immune responses by reprogramming tumor-associated macrophages, linking deubiquitinase regulation to immunotherapy.
• Experimental models for studying GO:2000158 include knockout, point-mutation, knock-in, and overexpression cell lines, combined with ubiquitination assays, proteomics, and CRISPR library screening.
Description
Ubiquitin-specific proteases (USPs), also known as deubiquitinases (DUBs), are enzymes that remove ubiquitin moieties from target proteins, thereby reversing ubiquitination and altering protein stability, localization, or activity. The Gene Ontology term GO:2000158, positive regulation of ubiquitin-specific protease activity, captures any process that activates or increases the frequency, rate or extent of this deubiquitinase activity. This regulatory process is critical because it determines the half-life and function of numerous proteins involved in cancer, immune signaling, and cardiac remodeling. Research over the past decade has revealed that positive regulation of USP activity is not a passive event but is tightly controlled by post-translational modifications, protein-protein interactions, and substrate availability. For example, USP35 stabilizes Snail1 to promote gastric cancer metastasis, while USP48 stabilizes Gasdermin E to promote pyroptosis in cancer. USP7 deubiquitinates KRAS and promotes non-small cell lung cancer, and USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma. These findings underscore the importance of understanding how deubiquitinase activity is positively regulated in both physiological and pathological contexts. For researchers, GO:2000158 provides a conceptual framework to study the upstream signals and molecular mechanisms that enhance USP activity. This article synthesizes authoritative QuickGO data and verified PubMed literature to describe the definition, biological significance, key genes, disease associations, and experimental methods for studying positive regulation of ubiquitin-specific protease activity.
positive regulation of ubiquitin-specific protease activity At A Glance
| GO ID | GO:2000158 |
|---|---|
| GO term | positive regulation of ubiquitin-specific protease activity |
| Ontology | biological_process |
| Synonym | positive regulation of deubiquitinase activity; positive regulation of ubiquitin hydrolase activity; positive regulation of UBP; positive regulation of UCH2 |
| Major function | Activates or increases the frequency, rate or extent of deubiquitinase activity, thereby stabilizing target proteins and modulating signaling pathways. |
| Related cellular process | Protein stabilization, ubiquitin-dependent proteolysis, signal transduction, immune response, and cancer progression. |
| Key deubiquitinases involved | USP35, USP48, USP7, USP22, USP38, USP1. |
| Disease relevance | Gastric cancer, non-small cell lung cancer, hepatocellular carcinoma, cardiac remodeling, cisplatin resistance, and atopic disorders. |
What Is GO:2000158?
GO:2000158, positive regulation of ubiquitin-specific protease activity, is a biological process defined as any process that activates or increases the frequency, rate or extent of ubiquitin-specific protease (deubiquitinase) activity. In other words, it encompasses the molecular events that boost the ability of USPs to cleave ubiquitin from substrate proteins, thereby opposing ubiquitination-mediated degradation or signaling.
Why Is positive regulation of ubiquitin-specific protease activity Important in Cell Biology?
Positive regulation of ubiquitin-specific protease activity is a central mechanism for controlling protein stability and signaling dynamics in cells. Because deubiquitinases can reverse ubiquitination, their activation can rapidly stabilize oncoproteins, immune regulators, and metabolic factors, making this process a key node in cancer, immunology, and cardiovascular disease. Understanding how USP activity is positively regulated offers opportunities for therapeutic intervention and biomarker discovery.
• Drives cancer metastasis by stabilizing Snail1 in gastric cancer.
• Promotes pyroptosis in cancer by stabilizing Gasdermin E.
• Enhances non-small cell lung cancer progression via KRAS stabilization.
• Regulates lipid metabolism and hepatocellular carcinoma through PPARγ stabilization.
• Aggravates pathological cardiac remodeling by stabilizing phospho-TBK1.
• Modulates cisplatin resistance through USP1 regulation of MAST1.
• Reprograms tumor-associated macrophages and anti-tumor immunity via USP7.
• Provides targets for CRISPR-based functional genomics and drug discovery.
• Links ubiquitin signaling to primary atopic disorders and immune dysregulation.
• Enables precise experimental modeling using knockout, knock-in, and overexpression systems.
What Happens During positive regulation of ubiquitin-specific protease activity?
Upstream signals that activate deubiquitinases
In simple terms: Certain cellular signals tell deubiquitinases to become more active.
Positive regulation of USP activity can be triggered by post-translational modifications, protein-protein interactions, or changes in substrate availability. For example, phosphorylation of TBK1 recruits USP38 to stabilize phospho-TBK1 during cardiac remodeling. Similarly, oncogenic signaling can enhance USP35 activity to stabilize Snail1 in gastric cancer.
Conformational changes and complex assembly
In simple terms: Deubiquitinases change shape or join partners to become fully active.
Activation often involves conformational changes or assembly into multi-protein complexes that increase catalytic efficiency. USP48 stabilizes Gasdermin E by deubiquitination, a process that may require interaction with adaptor proteins. USP22 regulates PPARγ stability, likely through complex formation with transcriptional cofactors.
Substrate recognition and deubiquitination
In simple terms: The activated deubiquitinase finds its target and removes ubiquitin.
Once activated, USPs recognize specific substrates and cleave ubiquitin chains, preventing degradation or altering signaling. USP7 deubiquitinates KRAS, leading to its stabilization and enhanced downstream signaling in non-small cell lung cancer. USP1 regulates MAST1-driven cisplatin resistance, demonstrating substrate-specific deubiquitination.
Downstream effects on protein stability and signaling
In simple terms: Removing ubiquitin changes what the target protein does.
Deubiquitination stabilizes target proteins, leading to altered cell proliferation, migration, immune evasion, or death. USP35-mediated Snail1 stabilization promotes epithelial-mesenchymal transition and metastasis. USP48-mediated Gasdermin E stabilization promotes pyroptosis, a form of inflammatory cell death. USP7 targeting reprograms tumor-associated macrophages, linking deubiquitination to anti-tumor immunity.
Key Genes Involved in GO:2000158 positive regulation of ubiquitin-specific protease activity
The following genes and proteins are central to the positive regulation of ubiquitin-specific protease activity, as supported by verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| USP35 | Stabilizes Snail1 to promote gastric cancer metastasis | Target for metastasis inhibition in gastric cancer |
| USP48 | Stabilizes Gasdermin E to promote pyroptosis in cancer | Modulator of inflammatory cell death in tumors |
| USP7 | Deubiquitinates KRAS and promotes non-small cell lung cancer; modulates anti-tumor immune response | Therapeutic target in lung cancer and immunotherapy |
| USP22 | Regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma | Metabolic target in liver cancer |
| USP38 | Aggravates pathological cardiac remodeling by stabilizing phospho-TBK1 | Potential target for heart failure |
| USP1 | Regulates MAST1-driven cisplatin resistance in cancer cells | Biomarker for chemotherapy response |
| TBK1 | Phosphorylated form stabilized by USP38 | Kinase involved in innate immunity and cardiac stress |
| PPARγ | Stabilized by USP22, regulates lipid metabolism | Nuclear receptor in metabolic disease and cancer |
| KRAS | Deubiquitinated by USP7, promotes lung cancer | Oncogene target in NSCLC |
| Snail1 | Stabilized by USP35, drives metastasis | Transcription factor in EMT |
| Gasdermin E | Stabilized by USP48, promotes pyroptosis | Executioner of pyroptosis |
| MAST1 | Regulated by USP1, mediates cisplatin resistance | Kinase target in chemoresistance |
| USP family members | Broadly regulate deubiquitination | CRISPR screening identifies novel family members |
| Tumor-associated macrophages | Reprogrammed by USP7 targeting | Immune microenvironment modulators |
| Atopic disorder genes | Identified via genomic sequencing in primary atopic disorders | Link between deubiquitination and immune dysregulation |
| Deubiquitinase subfamily | Genome-wide CRISPR screen identifies regulators | Functional genomics resource |
| Ubiquitin hydrolase UCH2 | Synonym for deubiquitinase activity | Historical nomenclature |
How Is positive regulation of ubiquitin-specific protease activity Regulated?
Positive regulation of ubiquitin-specific protease activity is controlled at multiple levels, including post-translational modifications of the deubiquitinase itself, interaction with regulatory partners, and substrate availability. For instance, phosphorylation of TBK1 creates a docking site for USP38, enhancing its deubiquitinase activity toward phospho-TBK1. In cancer, oncogenic signaling pathways can upregulate USP35 or USP7, leading to stabilization of Snail1 or KRAS, respectively. Additionally, CRISPR screening has revealed that deubiquitinase subfamily members such as USP1 are subject to regulation that affects cisplatin resistance. These regulatory layers ensure that deubiquitination is tightly controlled in response to cellular cues.
positive regulation of ubiquitin-specific protease activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| USP35 | Gastric cancer metastasis | Knockout and overexpression in gastric cancer cell lines |
| USP48 | Cancer pyroptosis | Point mutation and knock-in models to study Gasdermin E stabilization |
| USP7 | Non-small cell lung cancer; anti-tumor immunity | Knockout and overexpression in lung cancer and macrophage models |
| USP22 | Hepatocellular carcinoma lipid metabolism | Knockout and tagged knock-in in liver cancer cells |
| USP38 | Pathological cardiac remodeling | Knockout and overexpression in cardiomyocytes |
Cancer progression and metastasis
Positive regulation of USP activity is frequently hijacked in cancer to stabilize oncoproteins and promote metastasis. USP35 stabilizes Snail1, driving gastric cancer metastasis. USP7 deubiquitinates KRAS, enhancing non-small cell lung cancer growth. USP22 stabilizes PPARγ, contributing to hepatocellular carcinoma lipid accumulation. USP1 regulates MAST1-driven cisplatin resistance, linking deubiquitination to chemoresistance. These findings highlight deubiquitinases as therapeutic targets in multiple malignancies.
Inflammation and pyroptosis
USP48 stabilizes Gasdermin E to promote pyroptosis in cancer, suggesting that positive regulation of deubiquitinase activity can modulate inflammatory cell death. This has implications for cancer immunotherapy and inflammatory diseases. Additionally, USP7 targeting reprograms tumor-associated macrophages, linking deubiquitination to anti-tumor immune responses.
Cardiovascular remodeling
USP38 aggravates pathological cardiac remodeling by stabilizing phospho-TBK1, indicating that positive regulation of deubiquitinase activity contributes to heart failure pathogenesis. This opens avenues for targeting deubiquitinases in cardiovascular disease.
Immune dysregulation and atopic disorders
Rapid genomic sequencing has identified primary atopic disorders, some of which may involve deubiquitinase-related pathways. Although direct links are still emerging, the role of USP7 in macrophage reprogramming suggests broader immune regulatory functions.
From positive regulation of ubiquitin-specific protease activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of USP35 affect Snail1 stability and metastasis? | USP35 knockout gastric cancer cell line |
| Can point mutation of USP48 alter Gasdermin E deubiquitination? | USP48 point-mutation knock-in cancer cells |
| Does USP7 overexpression stabilize KRAS in lung cancer? | USP7 overexpression in NSCLC cell lines |
| How does USP22 regulate PPARγ in hepatocellular carcinoma? | USP22 knockout and tagged knock-in liver cancer cells |
| What is the role of USP38 in cardiac remodeling? | USP38 knockout and overexpression in cardiomyocytes |
| Which deubiquitinases mediate cisplatin resistance? | CRISPR/Cas9 genome-wide library screening in cancer cells |
How to Study the positive regulation of ubiquitin-specific protease activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR/Cas9 genome-wide screening | Identification of deubiquitinases regulating drug resistance | Discovering positive regulators of USP activity |
| Ubiquitination assay | Removal of ubiquitin from substrates | Measuring deubiquitinase activity |
| Proteomics | Protein stability and ubiquitination changes | Identifying substrates and interaction partners |
| Western blotting | Protein levels and ubiquitination status | Validating deubiquitination effects |
| Immunoprecipitation | Protein-protein interactions | Detecting USP-substrate complexes |
| Fluorescence microscopy | Protein localization and stability | Imaging phospho-TBK1 stabilization |
| Flow cytometry | Immune cell reprogramming | Analyzing tumor-associated macrophages |
| Genomic sequencing | Identification of atopic disorder variants | Clinical diagnosis of primary atopic disorders |
CRISPR/Cas9 genome-wide screening
CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily members has identified USP1 as a regulator of MAST1-driven cisplatin resistance, demonstrating the power of functional genomics to uncover positive regulators of USP activity. This method allows unbiased discovery of deubiquitinases that modulate drug response.
Ubiquitination and deubiquitination assays
In vitro and in vivo deubiquitination assays measure the removal of ubiquitin from substrate proteins, such as Snail1, Gasdermin E, KRAS, and PPARγ. These assays typically use immunoprecipitation followed by western blotting with ubiquitin-specific antibodies.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify changes in protein stability and ubiquitination sites following modulation of USP activity. Interactomics reveals binding partners that positively regulate deubiquitinases.
Imaging and phenotypic analysis
Fluorescence microscopy and live-cell imaging can track protein localization and stability, such as phospho-TBK1 stabilization by USP38 in cardiac remodeling. Phenotypic assays measure metastasis, pyroptosis, or lipid accumulation.
How CRISPR Can Be Used to Study GO:2000158 positive regulation of ubiquitin-specific protease activity
Knockout
CRISPR knockout of deubiquitinase genes such as USP35, USP48, USP7, USP22, and USP38 can reveal their necessity in stabilizing target proteins and driving disease phenotypes. For example, USP35 knockout reduces Snail1 stability and gastric cancer metastasis.
Point Mutation
Point mutations can be introduced into deubiquitinase catalytic domains or regulatory sites to dissect their mechanism of action. For instance, mutating the catalytic cysteine of USP48 can test its role in Gasdermin E stabilization.
Knock-in
Knock-in of tagged or mutant deubiquitinases allows precise tracking and functional analysis. Tagged knock-in of USP22 enables studies of its interaction with PPARγ in hepatocellular carcinoma.
Overexpression
Overexpression of deubiquitinases such as USP7 or USP38 can mimic positive regulation and drive oncogenic or cardiac phenotypes. USP7 overexpression stabilizes KRAS and promotes non-small cell lung cancer.
How EDITGENE Supports positive regulation of ubiquitin-specific protease activity Research
Researchers studying positive regulation of ubiquitin-specific protease activity-related genes often need to determine whether a candidate gene is causally involved in deubiquitination, protein stabilization, or disease progression. EDITGENE provides comprehensive CRISPR-based services to model these processes with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of ubiquitin-specific protease activity research.
Frequently Asked Questions About positive regulation of ubiquitin-specific protease activity
What is GO:2000158 positive regulation of ubiquitin-specific protease activity?
GO:2000158 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of ubiquitin-specific protease (deubiquitinase) activity.
What genes are involved in positive regulation of ubiquitin-specific protease activity?
Key genes include USP35, USP48, USP7, USP22, USP38, and USP1, which stabilize substrates such as Snail1, Gasdermin E, KRAS, PPARγ, phospho-TBK1, and MAST1.
How does positive regulation of deubiquitinase activity affect cancer?
It can stabilize oncoproteins like KRAS and Snail1, promote metastasis, and contribute to chemoresistance, as seen with USP35, USP7, and USP1.
What diseases are linked to GO:2000158?
Diseases include gastric cancer, non-small cell lung cancer, hepatocellular carcinoma, cardiac remodeling, cisplatin resistance, and primary atopic disorders.
What experimental models are used to study positive regulation of USP activity?
Common models include CRISPR knockout, point-mutation, knock-in, and overexpression cell lines, combined with ubiquitination assays and CRISPR library screening.
How can CRISPR screening identify regulators of deubiquitinase activity?
Genome-wide CRISPR/Cas9 screens can systematically knock out deubiquitinase subfamily members and identify those that regulate phenotypes such as cisplatin resistance.
What is the role of USP7 in non-small cell lung cancer?
USP7 deubiquitinates KRAS, promoting its stability and downstream signaling in non-small cell lung cancer.
How does USP48 regulate pyroptosis?
USP48 stabilizes Gasdermin E by deubiquitination, thereby promoting pyroptosis in cancer cells.
What is the link between USP22 and hepatocellular carcinoma?
USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma.
How does USP38 contribute to cardiac remodeling?
USP38 aggravates pathological cardiac remodeling by stabilizing phospho-TBK1.
Conclusion
Positive regulation of ubiquitin-specific protease activity (GO:2000158) is a critical biological process that controls protein stability and signaling through deubiquitination. Its dysregulation is implicated in cancer, cardiovascular disease, and immune disorders, making it a rich area for therapeutic targeting. Advances in CRISPR-based models and functional genomics continue to uncover new deubiquitinases and regulatory mechanisms. Researchers can leverage EDITGENE's comprehensive services to generate knockout, point-mutation, knock-in, and overexpression models, as well as CRISPR library screening and bioinformatics support, to accelerate discoveries in this field.
References
- 1. Ma C et al.. 2024. Ubiquitin-specific Protease 35 Promotes Gastric Cancer Metastasis by Increasing the Stability of Snail1.. Int J Biol Sci 20(3):953-967 PMID: 38250150
- 2. Ren Y et al.. 2023. USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer.. Cancer Res 83(7):1074-1093 PMID: 36607699
- 3. Huang B et al.. 2024. USP7 deubiquitinates KRAS and promotes non-small cell lung cancer.. Cell Rep 43(11):114917 PMID: 39499616
- 4. Ning Z et al.. 2022. USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma.. Nat Commun 13(1):2187 PMID: 35449157
- 5. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 6. Xiao Z et al.. 2024. Ubiquitin specific protease 38 aggravates pathological cardiac remodeling by stabilizing phospho-TBK1.. Int J Biol Sci 20(5):1815-1832 PMID: 38481817
- 7. Tyagi A et al.. 2022. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.. Theranostics 12(13):5949-5970 PMID: 35966591
- 8. Dai X et al.. 2020. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.. Theranostics 10(20):9332-9347 PMID: 32802195
